Recombinant Adeno-Associated Virus-Mediated Inhibiting of Interleukin-4 Expression in Rat Model of Asthma
Y Cao,WN Xiong,YJ Xu,ZX Zhang,BA Gao,CL Du,JY Lu,T Ye
DOI: https://doi.org/10.1097/00029330-200602010-00009
2006-01-01
Abstract:Asthma is a chronic disease characterized by reversible airway obstruction, airway hyperresponsiveness, and inflammation of airways. Th2 cells, one sort of CD4+ T lymphocytes, are currently considered to play an important role in the chronic airway inflammation of asthma. Meanwhile, a number of laboratories have clearly established the importance of the Th2-derived cytokine interleukin-4 (IL-4) in mediating the airway inflammatory response. Anti-IL-4 therapy might be beneficial in treatment of chronic asthma. Gene therapy represents a novel approach for treatment of asthma. Compared with other virus vectors, recombinant adeno-associated virus (rAAV) vector is one of the ideal vectors for gene therapy due to its non-pathogenicity and its ability to infect various types of cells.1 We constructed a rAAV vector expressing antisense oligonucleotide against IL-4 (rAAV-asIL4) and explored its effects on inhibiting the expression of IL-4 in asthma gene therapy in vitro and in vivo. METHODS Construction of AAV vector Plasmid psub201, AAV packaging plasmid pXX2 and Ad help plasmid pXX680 were provided by Dr. Richard Jude Samulski (University of North Carolina, USA). Plasmid pasIL4 and plasmid pRGFP were constructed by replacing Rep and Cap regions from psub201 with CMV-asIL4-polyA and CMV-GFP-polyA respectively, while the structure ITRs were remained.2 The rAAV-asIL4 and rAAV-GFP were made by a three-plasmid cotransfection into 293T cells as previously described.3 rAAV particles were subsequently purified by heparin affinity column chromatography.4 Titers of particle number were determined by quantitative DNA dot blot. The intensity of hybridization signals was analyzed on GDS8000 image analysis system (UVP, USA). Titers of rAAV-asIL4 and rAAV-GFP were both 5×1012 v.g/ml. Asthma model Forty-eight male Sprague-Dawley adult rats (Animal Apply Center, Tongji Medical College, China), weighing 180—200 g, were randomly divided into four groups (12 for each group): normal group, asthma group, rAAV-asIL4 treated group, and rAAV-GFP treated group. In each group, 6 rats were used for in vitro assay, and 6 for in vivo assay. The rats in asthma group, rAAV-asIL4 treated group, and rAAV-GFP treated group were sensitized by ovalbumin (Sigma, USA) and challenged with aerosolized according to the method of Molet et al.5 The rats in normal group were sensitized and challenged by PBS. In vitroandin vivoinfection For in vitro assay, CD4+ T cells were obtained and purified by negative selection with a magnetic cell sorter (R&D, USA), then were seeded in six-well plate at the density of 3×106 cells/well and incubated in DMEM containing 10% FCS, in the presence of 100 U/ml recombinant rat IL-2 (Peprotech, USA) and 10 μg/ml ConA (Sigma, USA) for 3 days. Then, rAAV-asIL4 and rAAV-GFP 4×104 v. g/ce Ils were added respectively. PBS was used in the normal and asthma groups. All the cells were cultured for 3 days before analysis. For in vivo assay, the rats in rAAV-asIL4 group and rAAV-GFP group were administered with rAAV-asIL4 and rAAV-GFP on day 0 and day 14 respectively by tail vein injection. At each time point, rAAV 0.5 ml was injected. Meanwhile, PBS was used in the normal and asthma groups. Semiquantitative RT-PCR Cultured CD4+ T lymphocytes, blood lymphocytes and right upper lung tissues were obtained and total RNA was isolated respectively using TRIzol (Invitrogen, USA). RT-PCR was performed as described in the RT-PCR kit (TaKaRa, Japan). β-actin (654 bp) served as endogenous control. The primers of β-actin used for PCR were 5′-AGGTCTTTACGGATGTCAACG-3′ and 5′- TGTCACCAACTGGGACGATA- 3′. The primers of IL-4 (352 bp) gene were 5′- ACCTTGCTGTCACCCTGTTC- 3′ and 5′- GTTGTGAGCGTGGACTCATTC- 3′. The cycling parameters for IL-4 PCR were as follows: 94°C for 5 minutes, 31 cycles at 94°C for 45 seconds, 57°C for 45 seconds, and 72°C for 60 seconds, and followed by the final step at 72°C for 10 minutes. ELISA The cell culture supernatants, bronchoalveolar lavage fluids (BALF) and sera were collected respectively. IL-4 was quantified using ELISA kits (Jingmei Biotech, China) according to the procedure recommended by the manufacturer. IgE in sera was measured using ELISA kits (Bethyl, USA). Briefly, the plate was coated with sheep anti-rat IgE-affinity purified antibody by incubating for 60 minutes. After blocked by blocking solution, samples were added and incubated for 60 minutes. Then, sheep anti-rat IgE-HRP conjugate was incubated for 60 minutes. All steps were performed at room temperature. TMB was used as enzyme substrate. Histopathological examination Right lower lung tissues were fixed in 10% formalin and embedded in paraffin. Three micron-thick sections were stained with hematoxylin and eosin. Statistical analysis Data were expressed as mean ± standard deviation (SD) and analyzed by one-way ANOVA and q test using SPSS 10.0. A P value less than 0.05 was considered statistically significant. RESULTS Inhibition of IL-4 mRNA and protein expression by rAAV-asIL4 administration Compared with normal group, the ovalbumin challenge in sensitized rats led to a drastic increase in the levels of IL-4 mRNA and protein expression. The levels of IL-4 mRNA and protein expression were not different between asthma group and rAAV-GFP treated group. However, administration of rAAV-asIL4 resulted in significant reduction in the levels of IL-4 mRNA and protein expression compared with that in the asthma or rAAV-GFP treated groups. (Table)Table: Interleukin-4 mRNA and protein expression in different groups (n=6)Inhibition of IgE by rAAV-asIL4 administration In rAAV-asIL4 treated group, the level of IgE in sera [(28.8 ± 8.0) ng/ml] was significant lower than that in the asthma group [(51.3 ± 8.2) ng/ml] and rAAV-GFP treated group [(51.0 ± 8.2) ng/ml, P<0.01]. Histopathological examination Lung sections in rAAV-asIL4 treated group revealed mild inflammation in peribronchial areas. rAAV-GFP treated group and asthma group rats showed severe peribronchial inflammation, bronchoconstriction and perivascular inflammation. (Fig.)Fig.: Lung tissues of rats in different group (HE, original magnification ×100). A: asthma group, B: rAAV-GFP treated group, C: normal group, D: rAAV-asIL4 treated group. rAAV-asIL4: recombinant adeno-associated virus vector expressing antisense oligonucleotide against interleukin-4.DISCUSSION The involvement of IL-4 in many processes of instigating and maintaining allergic inflammation makes it a key target for treating asthma. Molet et al5 reported that in asthma rats injected with IL-4 antisense oligodeoxynucleotide treated T cells, the late airways response, eosinophils, IL-4 and IL-5 expression were significantly decreased. Nishikubo et al6 reported that mice model of asthma which had been administered IL-4 antagonistic mutant DNA did not develop allergic inflammation. We explored the potential utility of long-term gene therapy for the treatment of asthma using rAAV-asIL4. In our experiment in vitro, the levels of IL-4 mRNA and proteins in rAAV-asIL4 treated group are much lower compared with that in the asthma or rAAV-GFP treated groups, suggesting that rAAV-asIL4 inhibits IL-4 secretion in CD4+ T lymphocytes and rAAV-asIL4 is constructed successfully. Further, in the experiment in vivo, rAAV-asIL4 is administrated to rat model of asthma by tail vein injection. IL-4 mRNA in peripheral blood lymphocytes and lung tissues is decreased. IL-4 protein in sera and BALF is also decreased. Previous data have shown that allergen-specific IgE mediates AHR and IL-4 promotes IgE synthesis. In this study, administration of rAAV-asIL4 resulted in a significant reduction of the level of IgE. In agreement with the results of IL-4 and IgE measurement, the pulmonary histopathological changes are less in rAAV-asIL4 treated group compared with that in the asthma and rAAV-GFP treated groups, indicating that antisense IL-4 has at least partly blocked allergy and asthma. While this result points to a potential clinical application of gene therapy for the treatment of asthma, many questions remain unresolved. In this study, an inhibitory effect on development of asthma is observed when a very high titer of rAAV-asIL4 is infected. However, it is difficult to use such a large amount of virus in human trials. Genetic capsid modifications being efficient re-targete of rAAV, tropism-modified rAAV vector may be a solution in future.7